{"prompt": "['CONFIDENTIAL', '204878 (ZOSTER-064)', 'Protocol Administrative Change 3 Final', \"Subject's characteristics and QoL scores reported at timepoints posterior to onset of\", 'HZ (Month 26 and Month 38) will be censored.', 'Further, details regarding the analysis will be provided in the statistical analysis plan.', '10.7.6.4. Analysis of safety by frailty status', 'This analysis of the safety data from the ZOSTER-064 population will be based on the', 'Total Vaccinated cohort for safety. Solicited, unsolicited and serious adverse events will', 'be analysed by baseline frailty status.', 'Incidences of SAEs during the 30-day (Days 0 - 29) follow-up period after each', 'vaccination, up to 8 months and during any time during the study classified according to', 'the MedDRA System Organ Class and Preferred Terms will be tabulated by frailty status.', '10.7.7.', 'Analysis of immunogenicity', 'The analysis will be based on the immunogenicity data from the ZOSTER-064', 'population for subjects in the adapted ATP for analysis of humoral immunogenicity, and', 'for subjects in the TVC for analysis of CMI, respectively (Section 10.5.3).', '10.7.7.1. Humoral immune response', 'Humoral immune response will be assessed and analysed by frailty status in the Humoral', 'Immunogenicity subset.', 'Descriptive statistics:', 'If the data allows the following parameters will be tabulated by vaccination group and', 'frailty status at Month 0, Month 3, Month 14, Month 26 and Month 38:', 'Geometric mean concentrations (GMCs) of anti-gE/anti-VZV Ab with 95% CIs;', 'Humoral seropositivity rates with exact 95% CIs;', 'Vaccine response rates with 95% CIs.', '10.7.7.2. Cell-mediated immune response', 'CMI response will only be assessed and analysed in the CMI component of the', 'Immunogenicity subset for subjects in the ZOSTER-006 study.', 'Descriptive statistics:', 'For CMI response; provided the data allows, the following parameters will be tabulated', 'by vaccination group and frailty status at Months 0, 3, 14, 26 and 38:', 'descriptive statistics of the frequency of CD4 T cell secreting at least two different', 'cytokines (IFN-y, IL-2, TNF-a,CD40L) to both VZV and gE antigens;', '11-FEB-2019', '39', '70882527ffe6806e42bab9a20b06541da11028ce']['CONFIDENTIAL', '204878 (ZOSTER-064)', 'Protocol Administrative Change 3 Final', 'descriptive statistics of the frequency of CD4 T cell secreting at least IFN-y and', 'another cytokine (IL-2, TNF-a,CD40L) to both VZV and gE antigens;', 'descriptive statistics of the frequency of CD4 T cell secreting at least IL-2 and', 'another cytokine (IFN-y, TNF-a,CD40L) to both VZV and gE antigens;', 'descriptive statistics of the frequency of CD4 T cell secreting at least TNF-a and', 'another cytokine (IFN-y, IL-2, CD40L) to both VZV and gE antigens;', 'descriptive statistics of the frequency of CD4 T cell secreting at least CD40L and', 'another cytokine (IFN-y, IL-2, TNF-a) to both VZV and gE antigens;', 'proportion of responders with exact 95% CI.', '10.8.', 'Interpretation of analyses', 'Comparative analyses will be descriptive with the aim to characterise the difference', 'between groups in the endpoint related to the objective. These descriptive analyses', 'should be interpreted with caution.', '10.9.', 'Conduct of analyses', 'Any deviation(s) or change(s) from the original statistical plan outlined in this protocol', 'will be described and justified in the final study report.', '10.9.1.', 'Sequence of analyses', 'There will be one analysis (final analysis) after completion of the data encoding.', '10.9.2.', 'Statistical considerations for interim analyses', 'All analyses will be conducted on final data and therefore no statistical adjustment for', 'interim analyses is required.', '11-FEB-2019', '40', '70882527ffe6806e42bab9a20b06541da11028ce']\n\n###\n\n", "completion": "END"}